share_log

BRIEF-Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

reuters ·  Nov 24, 2021 08:24

Nov 24 (Reuters) - Seelos Therapeutics Inc SEEL.O :

* SEELOS THERAPEUTICS ANNOUNCES ACQUISITION OF AN EXCLUSIVE LICENSE OF IX BIOPHARMA'S PROPRIETARY WAFER-BASED DELIVERY PLATFORM FOR SUBLINGUAL KETAMINE

* SEELOS THERAPEUTICS INC - NEW SLS-003 PROGRAM EXTENDS SEELOS' KETAMINE FRANCHISE INTO ADDITIONAL INDICATIONS INCLUDING CHRONIC NEUROPATHIC PAIN

* SEELOS THERAPEUTICS INC - SEELOS PLANS TO EVALUATE SUBLINGUAL KETAMINE, NOW NAMED SLS-003, IN PAIN INDICATIONS

* SEELOS THERAPEUTICS INC - PURSUANT TO LICENSE AGREEMENT, SEELOS WILL PAY IX BIOPHARMA A ONE-TIME, UPFRONT FEE OF $9 MILLION

Source text for Eikon: ID:nPn7sB5Xna Further company coverage: SEEL.O

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment